US 11,864,725 B2
Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
John Y. Chang, Los Altos, CA (US); and Joshua Makower, Los Altos, CA (US)
Assigned to Acclarent, Inc., Irvine, CA (US)
Filed by Acclarent, Inc., Irvine, CA (US)
Filed on Aug. 6, 2019, as Appl. No. 16/532,678.
Application 16/532,678 is a continuation of application No. 15/443,319, filed on Feb. 27, 2017, granted, now 10,492,810.
Application 15/443,319 is a continuation of application No. 15/363,002, filed on Nov. 29, 2016, abandoned.
Application 15/363,002 is a continuation of application No. 13/867,972, filed on Apr. 22, 2013, abandoned.
Application 13/867,972 is a continuation of application No. 12/649,050, filed on Dec. 29, 2009, granted, now 8,425,457, issued on Apr. 23, 2013.
Application 12/649,050 is a continuation of application No. 10/829,917, filed on Apr. 21, 2004, granted, now 7,654,997, issued on Feb. 2, 2010.
Prior Publication US 2020/0022717 A1, Jan. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 17/24 (2006.01); A61F 2/82 (2013.01); A61B 17/3207 (2006.01); A61M 29/02 (2006.01); A61B 17/3205 (2006.01); A61F 11/20 (2022.01); A61B 1/233 (2006.01); A61B 10/02 (2006.01); A61B 10/06 (2006.01); A61B 17/02 (2006.01); A61B 17/16 (2006.01); A61B 17/29 (2006.01); A61B 17/3201 (2006.01); A61B 18/02 (2006.01); A61B 18/04 (2006.01); A61B 18/12 (2006.01); A61B 18/18 (2006.01); A61F 2/18 (2006.01); A61F 13/20 (2006.01); A61M 16/04 (2006.01); A61M 25/10 (2013.01); A61M 31/00 (2006.01); A61N 1/05 (2006.01); A61B 17/34 (2006.01); A61B 17/22 (2006.01); A61B 1/313 (2006.01); A61B 17/32 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61B 18/14 (2006.01)
CPC A61B 17/24 (2013.01) [A61B 1/233 (2013.01); A61B 10/0233 (2013.01); A61B 10/06 (2013.01); A61B 17/0218 (2013.01); A61B 17/1688 (2013.01); A61B 17/29 (2013.01); A61B 17/3201 (2013.01); A61B 17/32053 (2013.01); A61B 17/32056 (2013.01); A61B 17/320725 (2013.01); A61B 17/320758 (2013.01); A61B 17/320783 (2013.01); A61B 18/02 (2013.01); A61B 18/042 (2013.01); A61B 18/12 (2013.01); A61B 18/18 (2013.01); A61F 2/186 (2013.01); A61F 2/82 (2013.01); A61F 11/20 (2022.01); A61F 13/2005 (2013.01); A61M 16/0434 (2013.01); A61M 25/10 (2013.01); A61M 29/02 (2013.01); A61M 31/00 (2013.01); A61M 31/005 (2013.01); A61N 1/0541 (2013.01); A61B 1/313 (2013.01); A61B 17/3478 (2013.01); A61B 2017/00477 (2013.01); A61B 2017/22061 (2013.01); A61B 2017/320052 (2013.01); A61B 2017/320064 (2013.01); A61B 2018/00327 (2013.01); A61B 2018/00595 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/1405 (2013.01); A61B 2217/005 (2013.01); A61B 2217/007 (2013.01); A61F 2/18 (2013.01); A61F 2250/0039 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method comprising:
(a) inserting a balloon catheter into a nasal cavity of a patient, the balloon catheter including a catheter shaft and a balloon positioned at a distal end of the catheter shaft, the balloon including a blade;
(b) positioning the balloon of the balloon catheter at least partially within a meatus of the nasal cavity;
(c) expanding the balloon to thereby dilate the meatus;
(d) cutting the meatus with the blade to control a fracturing of tissue during expansion of the balloon; and
(e) delivering a therapeutic agent that includes a steroid to the passageway from the expanded balloon as an exterior surface of the balloon is in direct contact with an inner surface of the meatus.